Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

The sac-TMT abstract is the biggest pre-ASCO data point. A 65% reduction in progression risk when an ADC is added to the world's best-selling drug, in the world's largest oncology indication, is a practice-changing result. Keytruda alone is the standard of care for PD-L1-positive first-line NSCLC. Adding sac-TMT to Keytruda nearly doubled the efficacy on PFS. The preliminary 45% OS trend, while immature, points in the same direction. If confirmed at the full presentation, this would be the strongest data supporting ADC-plus-checkpoint-inhibitor combination therapy in lung cancer to date. For Merck, this is the Keytruda succession story coming to life: sac-TMT does not replace Keytruda, it makes Keytruda better. A combination regimen would extend the Keytruda franchise beyond its 2028 patent expiration by making it part of a new standard of care that requires both agents. This is the same thesis we highlighted when Merck's sac-TMT hit Phase 3 in endometrial cancer on May 20. Now the data extend to lung cancer, a far larger market. ASCO opens tomorrow with more than 7,000 abstracts spanning oncology's most active areas: ADCs, bispecific antibodies, RAS inhibitors, radiopharmaceuticals, and cell therapy. Revolution Medicines' plenary on Saturday is the headliner, but the sac-TMT abstract, the Akeso ivonescimab OS data, and the J&J Erleada prostate data will all generate significant commercial attention. 👉 Read Full Analysis

🔮 What To Watch

🔬 Clinical & Research Updates

sac-TMT Plus Keytruda Cuts Progression Risk by 65% in First-Line Lung Cancer MRK

What Happened: ASCO abstracts released ahead of the meeting revealed that Merck and Kelun-Biotech's sacituzumab tirumotecan (sac-TMT), a Trop-2 directed antibody-drug conjugate, reduced the risk of disease progression or death by 65% when combined with Keytruda versus Keytruda alone in treatment-naive, PD-L1-positive non-small cell lung cancer. The data come from the Phase 3 OptiTROP-Lung05 trial conducted in China.

The Data: The combination achieved a statistically significant PFS improvement (HR 0.35, p<0.0001). A preliminary overall survival analysis showed a 45% improvement in favor of the combination arm, but OS was not mature at the September 29, 2025 data cutoff. Fierce Pharma noted this is "the first randomized Phase 3 data showing a Trop-2 ADC can meaningfully improve outcomes" in first-line NSCLC when added to a checkpoint inhibitor.

Executive Impact: This is the second major Phase 3 win for sac-TMT in a month (after the endometrial cancer data on May 20). The Kelun-Biotech partnership is proving to be one of the most productive China licensing deals in the industry. For Merck, sac-TMT plus Keytruda in first-line NSCLC could extend the Keytruda franchise well beyond its 2028 patent expiration by making the combination the new standard of care. Merck's global trial (TroFuse-007) is evaluating the same combination in PD-L1-high NSCLC patients and will be the basis for U.S. and global regulatory submissions.

📊 ASCO Plenary Preview: Three Sessions That Could Move Markets

1. Revolution Medicines RASolute 302 (Saturday) Full Phase 3 data in second-line pancreatic cancer. We know: 13.2 months OS vs. 6.7 months, HR 0.40. We need: PFS data, subgroup analyses, mature survival curves, safety details. Truist projects Q3 approval under CNPV.

2. Akeso Ivonescimab HARMONi-6 OS (Saturday) Overall survival data for the PD-1/VEGF bispecific antibody in squamous NSCLC. Ivonescimab previously showed a 40% PFS improvement over tislelizumab plus chemo, and separately beat Keytruda in PFS in HARMONi-02. OS data will determine whether a Chinese bispecific can challenge the global IO standard of care.

3. J&J Erleada PROTEUS (Saturday, opens plenary) Data described as a potential "paradigm shift" in high-risk localized or locally advanced prostate cancer. Erleada (apalutamide) is already approved in metastatic and non-metastatic castration-resistant prostate cancer. A positive PROTEUS result would expand the label into earlier disease stages.

🌍 Policy & Geopolitical

Push to Restrict U.S. Capital Flows to Chinese Biotech

Fierce Biotech reported that a growing coalition in Congress wants biotechnology added to the COINS Act, which would restrict outbound U.S. capital flows to designated sectors in countries of concern, including China. If enacted, this would directly affect U.S. venture capital and private equity investment in Chinese biotech companies, and could complicate the licensing pipeline that has been one of the defining trends of 2026. Companies with significant China licensing exposure include BMS/Hengrui ($15.2B), Lilly/Hengrui (via Kailera), Merck/Kelun-Biotech (sac-TMT), GSK/SiranBio ($1B), and AbbVie/Haisco. The provision has not yet passed but the political momentum is building.

📅 The Week Ahead

👉 Read Full Analysis

Keytruda faces LOE in 2028. Merck has been building a post-Keytruda portfolio centered on the Kelun-Biotech ADC partnership. The sac-TMT data are now the strongest evidence that this strategy is working:

The combination approach is the key insight. sac-TMT does not replace Keytruda. It makes Keytruda better. A Keytruda plus sac-TMT combination in first-line NSCLC would create a new regimen that requires both agents, extending Keytruda's commercial life even after generic pembrolizumab enters the market.

The China-to-global bridge: OptiTROP-Lung05 was conducted in China. TroFuse-007 (Merck's global study) is the basis for worldwide regulatory submissions. The China data serve as a proof of concept; the global data will determine the label.

💊 ASCO by the Numbers

📊 COINS Act: The China Capital Risk

If biotechnology is added to the COINS Act, U.S. investors would face restrictions on investing in Chinese biotech companies and potentially in U.S. companies with significant Chinese partnerships. The 2026 China licensing wave includes:

The legislation would not retroactively unwind existing deals but could freeze new investments and complicate future milestone payments and royalty structures. The political pressure is real: China's biotech sector is growing rapidly, and U.S. policymakers increasingly view it as both a competitive threat and a national security concern.

🎯 Catalyst Calendar: ASCO and Beyond

👉 Visit The Pro Hub

Limited ASCO-week sponsorship slots available (May 29 - June 2). Reach 65,000+ professionals during the biggest oncology event of the year. Learn more →

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →